Shangya Technology Co., Ltd. (TPEX:6130)
Taiwan · Delayed Price · Currency is TWD 24.70
-2.25 (-8.35%)
Apr 1, 2026, 1:30 PM CST
Shangya Technology Revenue
In the year 2025, Shangya Technology had annual revenue of 154.74M TWD, down -20.79%. Shangya Technology had revenue of 37.18M in the quarter ending December 31, 2025, a decrease of -11.94%.
Revenue
154.74M
Revenue Growth
-20.79%
P/S Ratio
7.07
Revenue / Employee
4.99M
Employees
31
Market Cap
1.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.74M | -40.62M | -20.79% |
| Dec 31, 2024 | 195.35M | -35.76M | -15.47% |
| Dec 31, 2023 | 231.12M | 145.95M | 171.36% |
| Dec 31, 2022 | 85.17M | -18.65M | -17.96% |
| Dec 31, 2021 | 103.82M | -34.06M | -24.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| Bora Pharmaceuticals | 19.01B |
| PharmaEssentia | 15.63B |
| AViTA | 936.39M |
| Excelsior Biopharma | 898.26M |
| DV Biomed | 712.61M |
| Genetics Generation Advancement | 603.11M |
| Meribank Biotech | 486.52M |